An allogeneic NK cell line engineered to express chimeric antigen receptors: Anovel strategy of cellular immunotherapy against cancer.

摘要

In recent years, several immunotherapeutic approaches against cancer have emerged, including the adoptive transfer of T cells that have been reprogrammed to react against one or more tumor-associated antigens (TAAs). In most cases, reprogramming is achieved as T cells are engineered to express the antigen-binding domain of a TAA-specific monoclonal antibody fused to intracellular domains that are normally involved in T-cell receptor (TCR) signaling and/or co-stimulation. In small cohorts of patients affected by hematological malignancies including both low-grade and aggressive B-cell neoplasms, significant, long-lasting clinical responses were observed upon the administration of these chimeric antigen receptor (CAR)-expressing T cells.